Free shipping on all orders over $ 500


Cat. No. M6218
Trastuzumab Structure


Size Price Availability Quantity
5mg USD 650  USD650 In stock
10mg USD 920  USD920 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: Trastuzumab has been demonstrated to exert a variety of anti-tumor effects selectively in HER2-overexpressing tumor cells. Trastuzumab binds to the juxtamembrane domain of HER2 and upon receptor binding, the antibody downregulates the expression of HER2. Trastuzumab selectively blocks ligand-independent HER2-HER3 dimerization. In addition, trastuzumab binding to HER2 blocks proteolytic cleavage of the extracellular domain of HER2, resulting in diminished levels of the more active p95-HER2 form of HER2. As a result of these effects on the HER2 receptor, trastuzumab causes downregulation of PI3K pathway signaling and downstream mediators of cell cycle progression such as cyclin D1. Trastuzumab not only inhibits HER2 signaling pathways but also triggers immune-mediated responses against HER2-overexpressing cells. Trastuzumab binding engages Fc receptors on immune effector cells leading to antibody-dependent cellular cytotoxicity. Beyond these effects, trastuzumab has been shown to have antiangiogenic effects and to lower the proapoptotic threshold for chemotherapy.

In vivo: Trastuzumab is shown to be safe when administered chronically to a range of animals including primates. In experiments mimicking adjuvant therapy of submacroscopic disease in vivo (JIMT-1 cells inoculated s.c. in severe combined immunodeficiency mice), trastuzumab is able to inhibit the outgrowth of macroscopically detectable xenograft tumors for up to 5-7 weeks. Trastuzumab has a remarkable antitumor effect and is currently used worldwide for the treatment of breast cancer. In in vivo models, trastuzumab decreases the microvessel density of breast cancer xenografts. It is well documented that trastuzumab acts directly in cancer cell signaling, as well as indirectly via the immune system.

Product Citations
Protocol (for reference only)
Cell Experiment
Cell lines JIMT-1, SKBR-3, and BT-474 cells
Preparation method Exponentially growing cells are harvested and plated in single wells of a 96-well flat-bottomed tissue culture plate at defined densities, ranging from 4,500–8,000 cells per well depending on the cell line. After overnight culture, the regular medium is exchanged to medium containing 0, 1, 10, or 100 μg/mL trastuzumab or trastuzumab-F(ab′)2. Cell viability is tested after 72 h of treatment. Fluorescence is detected at an excitation of 544 nm, and emission is detected at 590 nm.
Concentrations 0, 1, 10, or 100 μg/mL
Incubation time 72 h
Animal Experiment
Animal models SCID C.B-17 scid/scid and nu/nmri nude mouse
Formulation saline
Dosages 5 μg/g
Administration i.p.
Chemical Information
Molecular Weight 145529.41
Formula C6470H10012N1726O2013S42
CAS Number 180288-69-1
Storage Store at -20°C or -70°C. Avoid multiple freeze-thaws.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Okita R, et al. Oncol Rep. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.

[2] Han X, et al. Oncotarget. Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo.

[3] Hiroshima Y, et al. PLoS One. Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Pat ient-Derived Mouse Models.

[4] Nahta R, et al. Oncogene. Trastuzumab: triumphs and tribulations.

Related EGFR/HER2 Products

Unecritinib is a potent EGFR tyrosine kinase inhibitor that inhibits ALK, ROS1, and MET and has anticancer activity. Unecritinib is indicated for use in studies of solid tumors and ALK-positive anaplastic large cell lymphoma.

Almonertinib mesylate

Almonertinib mesylate is an orally active, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR sensitization and T790M resistance mutations, and also shows strong inhibitory activity against T790M, T790M/L858R, and T790M/Del19, with IC50 of 0.37, 0.29, and 0.21 nM, respectively. The IC50 of T790M/Del19 was 0.37, 0.29 and 0.21 nM, respectively, but the inhibitory effect on wild-type was weaker, with an IC50 of 3.39 nM. It can be used in the research of non-small cell lung cancer.


MAPK-IN-2 is a potent MAPK inhibitor with antineoplastic activity.


EGFR-IN-81 is an EGFR inhibitor.


EGFR-IN-85 is an EGFR inhibitor.

Abmole Inhibitor Catalog

Keywords: Trastuzumab, Herceptin supplier, EGFR/HER2, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.